Sage Drug Could Help Take Stigma Out Of Postpartum Depression
Executive Summary
SAGE Therapeutics Inc. could offer the one in eight new mothers suffering from postpartum depression (PPD) freedom from the overwhelming condition with the first-ever drug to specifically treat PPD if the rapid and durable response to SAGE-547 in a small Phase II clinical trial holds up in future studies.
You may also be interested in...
All Smiles At Sage As Phase III Postpartum Depression Data Are Positive
The company plans to file an NDA with FDA in the first half of 2018 for an intravenous formulation of brexanolone, which could be the first treatment specifically for postpartum depression.
Sage Therapeutics on PRIME, Partnerships and Pricing For Its PPD First
Sage Therapeutics is on track to deliver the first ever drug to be indicated for postpartum depression. The company discusses plans for launch and whether or not it wants to partner.
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.